From IBS Misdiagnosis to Parasitic Resolution A Clinical Case Study in Comprehensive Parasitology and 12-Week Elimination

This clinical case study documents the diagnostic journey and treatment outcomes of a 42-year-old female patient who presented with chronic digestive symptoms, anxiety, fatigue, and dermatologic manifestations after receiving an irritable bowel syndrome diagnosis from seven prior physicians. Comprehensive parasitological testing revealed Blastocystis hominis and Strongyloides stercoralis co-infection missed by prior single-sample stool examinations. A 12-week elimination protocol incorporating pharmaceutical and herbal anti-parasitic agents, supported by structured die-off management and a 20-week gut restoration program, resulted in resolution of both digestive and systemic symptoms. This case illustrates the clinical consequences of inadequate parasitic testing and the therapeutic potential of comprehensive elimination and restoration protocols.

Key Clinical Takeaways

• Seven-physician diagnostic odyssey resolved by comprehensive testing — single-sample stool O&P exams performed by prior clinicians missed dual parasitic infection that three-day comprehensive parasitology with PCR identified immediately
• Blastocystis and Strongyloides co-infection produced multi-system symptoms — the combination of a gut-destroying protozoan and an auto-infecting nematode generated digestive, dermatologic, psychiatric, and respiratory manifestations that appeared unrelated under conventional diagnostic frameworks
• The 12-week elimination protocol achieved complete organism eradication — a structured build-maintain-taper approach using the Holy Trinity herbal protocol alongside pharmaceutical anti-parasitics resolved infection confirmed by follow-up testing
• Die-off management determined protocol tolerability and completion — without structured Herxheimer management using binders, hydration, and dose modification, the patient would have discontinued treatment during the peak elimination phase
• Gut restoration was essential for sustained symptom resolution — organism elimination alone did not resolve all symptoms; the 4R gut restoration program (Remove, Repair, Reinoculate, Rebalance) was necessary to reverse parasite-induced intestinal barrier damage

Patient Presentation: The Clinical Picture That Missed Its Diagnosis

Patient: M.R., 42-year-old female, marketing executive Chief Complaint: “My gut controls my life and no one can tell me why” Duration of Symptoms: 6 years Prior Diagnoses: Irritable bowel syndrome (3 physicians), generalized anxiety disorder (2 physicians), chronic fatigue syndrome (1 physician), fibromyalgia (1 physician) Prior Treatments: Rifaximin (2 courses), dicyclomine, escitalopram 20mg, gabapentin 300mg TID, polyethylene glycol, low-FODMAP diet Total Prior Physicians: 7

M.R. presented to the clinic with a six-year history of progressive, multi-system symptoms that had been evaluated by seven different physicians across gastroenterology, psychiatry, and primary care. Her symptom portfolio had expanded steadily over the years, with each new manifestation receiving its own diagnostic label and pharmacologic intervention. None of the interventions had produced sustained improvement.

Symptom Inventory at Initial Evaluation

Digestive:

• Daily bloating with visible abdominal distension beginning 30 minutes after meals
• Alternating constipation (3-4 days) and loose stools (2-3 episodes during loose phases)
• Post-prandial nausea, particularly after fat-containing meals
• Sensitivity to an expanding list of foods that had progressed from dairy and gluten to include onions, garlic, apples, and most fermented products

Systemic:

• Fatigue rated 3/10 on self-assessment (“I operate at 30% of my former capacity”)
• Unrefreshing sleep with consistent 3 AM awakenings accompanied by racing thoughts and mild diaphoresis
• Brain fog: difficulty with word retrieval, reduced processing speed, inability to sustain attention through afternoon meetings
• Migrating skin rashes on torso and upper thighs, appearing intermittently, lasting 2-5 days, unresponsive to antihistamines and topical corticosteroids
• Nocturnal anal pruritus disrupting sleep onset
• Teeth grinding confirmed by dentist (significant enamel wear requiring night guard)
• Unexplained weight gain of 18 lbs over 4 years despite dietary restriction
• New-onset sugar cravings that she described as “biologically irresistible”

Psychiatric:

• Anxiety with prominent somatic features (palpitations, chest tightness, dread) worsening in late afternoon and evening
• Depressive episodes lasting 1-2 weeks, occurring approximately every 6 weeks
• Sense of internal restlessness and irritability
• Panic-like episodes occurring 2-3 times monthly without identifiable psychological triggers

Respiratory:

• Intermittent dry cough not associated with illness or allergy season
• Mild wheezing with exercise, which she had never experienced before symptom onset

Prior Laboratory Findings

• CBC with differential: WBC 6.2, eosinophils 7.2% (flagged as “slightly elevated” but not investigated further)
• Standard stool O&P (single sample, processed at commercial lab): negative
• Comprehensive metabolic panel: normal
• Thyroid panel: TSH 3.8 mIU/L (within reference range), free T4 0.9 ng/dL (low-normal)
• C-reactive protein: 4.2 mg/L (elevated above optimal but below conventional cutoff for significance)
• Anti-TPO antibodies: 68 IU/mL (elevated, consistent with early Hashimoto’s thyroiditis)
• Vitamin D: 22 ng/mL (deficient)
• Vitamin B12: 312 pg/mL (within reference range but below optimal threshold)
• Ferritin: 28 ng/mL (functional iron deficiency)

The eosinophilia of 7.2% was the most diagnostically significant finding in retrospect — a marker of tissue-invasive parasitic infection that was noted but not pursued by prior clinicians. In the context of her respiratory and dermatologic symptoms, it should have triggered comprehensive parasitological evaluation. It did not.

The Diagnostic Breakthrough: Comprehensive Parasitology

Given the clinical presentation — multi-system symptoms, eosinophilia, nocturnal symptom predominance, migrating rashes, and treatment resistance across conventional interventions — comprehensive parasitological testing was ordered:

Testing Performed

1. Comprehensive Stool Parasitology (Genova Diagnostics GI Effects): 3-day collection with concentration, trichrome and acid-fast stains, antigen detection, and PCR
2. Strongyloides antibody panel (serology via LabCorp)
3. Toxoplasma gondii IgG/IgM (serology)
4. CBC with differential (repeat)

Results

• Blastocystis hominis: Positive (moderate load) — detected by PCR and confirmed on trichrome stain. This organism was not detected on prior single-sample O&P examinations.
• Strongyloides stercoralis: Positive IgG antibody (1.8 IV, reference <1.0) — consistent with chronic infection. Stool PCR also detected Strongyloides DNA.
• Toxoplasma gondii: IgG positive (48 IU/mL), IgM negative — consistent with prior exposure, not active acute infection
• CBC eosinophils: 8.1% (increased from prior 7.2%, consistent with active tissue-invasive helminth infection)

The diagnosis was clear: Blastocystis hominis and Strongyloides stercoralis co-infection. Two parasitic organisms, both capable of producing chronic, multi-system symptoms, both missed by the standard single-sample O&P exams that had been performed years earlier. The Blastocystis was driving the digestive symptoms, the systemic inflammation, the anxiety and depression. The Strongyloides was driving the migrating rashes (larva currens), the respiratory symptoms (pulmonary larval migration), and contributing to the eosinophilia and nocturnal symptom pattern.

The Toxoplasma IgG seropositivity was noted but not treated as an active infection — it represented prior exposure consistent with the CDC’s estimate of 60+ million seropositive Americans. However, its contribution to the patient’s cognitive symptoms could not be excluded entirely and was monitored.

The 12-Week Elimination Protocol: Structure and Execution

Treatment was structured using a phased elimination framework designed to maximize organism eradication while managing the inflammatory consequences of parasitic die-off.

Phase 1: Preparation (Weeks 1-2)

Objective: Optimize elimination pathways, support hepatic detoxification, establish hydration baseline, and introduce gentle anti-parasitic foods before active elimination.

Protocol:

• Hydration: minimum 3 liters filtered water daily with electrolytes
• Liver support: N-acetylcysteine 600mg BID, milk thistle 150mg BID
• Bowel regularity: magnesium citrate 400mg at bedtime, ensuring daily bowel movements
• Gentle anti-parasitic foods: 2-4 cloves raw garlic daily, 1/4 cup pumpkin seeds, 1-2 tbsp coconut oil
• Dietary: elimination of processed sugar, refined carbohydrates, and alcohol to reduce organism substrate

Patient Response: Mild improvement in bloating within the first week. No adverse effects. Patient reported feeling “cautiously optimistic” for the first time in years.

Phase 2: Active Elimination (Weeks 3-8)

Objective: Systematic eradication of Blastocystis and Strongyloides using a combined pharmaceutical and herbal approach.

Pharmaceutical Component:

• Ivermectin: 200 mcg/kg single dose (Week 3) — targeting Strongyloides as first-line therapy per CDC treatment guidelines
• Albendazole: 400mg BID with fatty meals for 7 days (Week 4) — broad-spectrum coverage for potential tissue-invasive helminths; taken with fatty meal for 4-5x absorption enhancement
• Nitazoxanide: 500mg BID for 14 days (Weeks 3-5) — targeting Blastocystis hominis (off-label use supported by clinical evidence)

Herbal Component (Holy Trinity):

• Wormwood (Artemisia absinthium): 500mg TID — built up from 250mg TID in Week 3 to full dose by Week 5
• Black Walnut Hull tincture: 15 drops BID — built up from 5 drops BID in Week 3 to full dose by Week 5
• Clove (Eugenia caryophyllata): 500mg TID — targeting parasite eggs and larvae to prevent re-infection from hatching cycles

Peak Elimination (Week 5): Full doses of all agents concurrent. This was the phase where die-off symptoms were most intense.

Taper (Weeks 6-8): Gradual reduction of herbal doses back to maintenance levels as organism burden decreased.

Die-Off Management: The Critical Determinant of Protocol Completion

The Herxheimer-type reaction during peak elimination was the most challenging phase of the protocol. Understanding and managing die-off was essential for treatment completion.

Week 5 Die-Off Experience:

Mild symptoms (Days 1-2): Increased fatigue, mild headache, generalized malaise. Patient continued full protocol with increased hydration to 4 liters daily.

Moderate symptoms (Days 3-4): Significant bloating, flu-like myalgias, irritability, heightened anxiety (2-3x baseline). Activated charcoal 500mg BID was added 2 hours away from anti-parasitic agents. Patient rested as needed.

Significant symptoms (Days 5-6): Intensity reached 7/10. Migrating rash flared dramatically (consistent with Strongyloides die-off releasing tissue-localized antigens). Brain fog severe. Patient reduced wormwood dose to 50% (250mg TID) for 48 hours while maintaining charcoal 750mg BID and hydration. Epsom salt baths (2 cups, 20 minutes) provided symptomatic relief.

Resolution (Days 7-10): Symptoms gradually subsided to moderate then mild. Full wormwood dose was resumed on Day 7. By Day 10, patient reported feeling “significantly different” — specifically, the 3 AM wake-ups had ceased for the first time in years, and the brain fog had notably improved.

For structured protocols and implementation guidance, visit Human Optimization Lab.